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Subunit composition of proteasomes isolated from the colon 
of control patients and patients with IBD. Purified 20S pro-
teasomes from the colonic mucosa were separated by 2-DE, 
and spots were identified by MALDI-MS. (A) 20S proteasome 
subunit pattern of control patients (n = 6); lines indicate differ-
ent isoforms of individual subunits. (B and C) Subunit com-
position of 20S proteasomes derived from noninflamed and 
inflamed mucosa of the colon from UC patients (UC, non-
inflamed tissue, n = 5; UC, inflamed tissue, n = 5) and CD 
patients (CD, noninflamed tissue, n = 5; CD, inflamed tissue, 
n = 5). Circles indicate increased expression of immunosub-
units in inflamed mucosa of CD. Shown are representative 
2-DE gels of 5 independent experiments.
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Proteolytic activity of proteasomes in IBD 
patients. (A–C) Enzymatic activity of 20S 
proteasomes purified from colonic mucosa 
of CD patients (filled squares), UC patients 
(triangles), and control patients (circles) was 
measured by cleavage of fluorogenic peptide 
substrates. Control reaction was performed 
in the presence of the proteasome inhibitor 
MG132 (open squares). Data are expressed 
as means ± SEM. (n = 5). Statistical sig-
nificance was determined by 1-way ANOVA 
(chymotrypsin- and caspase-like activity, 
P < 0.001; trypsin-like activity, P = 0.114). (D) 
Western blot of lysates from inflamed intesti-
nal mucosa of CD patients, UC patients, and 
controls was stained for the proteasomal 
immunosubunit β1 and β-actin. (E) Quanti-
tative analysis of the proteasomal β1/β-actin 
protein ratio was performed using AIDA 
Image Analyser software (version 4.0.3; 
Raytest). Data represent means ± SEM; CD 
(n = 10), UC (n = 10), and controls (n = 9). 
*P < 0.05, Student’s t test (n = 9–10).
Figure 3
Expression of immunoproteasomes in 
the intestinal mucosa of IBD patients. (A 
and B) Immunofluorescent staining of 
sections from the terminal ileum (A) and 
colon (B) of IBD patients and controls 
with an antibody to β2i. Magnification, 
×200 (A, upper panel); ×1000 (A, lower 
panel, and B). (C) Inflammation scores of 
patients shown in A and B (CD, n = 10; 
UC, n = 8; control, n = 10; ***P < 0.001 
compared with control).
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Proteasomal processing of NF-κB precursor protein 
p105. (A) Kinetics of processing of p105 by pro-
teasomes from the colonic mucosa of IBD patients 
and controls (CD, n = 6; UC, n = 5; controls, n = 5). 
35S-labeled in vitro–translated p105 (Supplemen-
tal Figure 1) was incubated with cytosolic lysates 
of colonic tissues in the presence of 10 mM ATP. 
A representative autoradiogram is shown for each 
group of patients. (B) Detailed analysis of pro-
cessing of p105 during first 20 minutes by lysates 
from CD patients. (C) Processing of p105 in the 
absence of ATP by lysates from CD patients. (D) 
Quantitative analysis of autoradiograms, showing 
significant differences in the processing of p105 
among CD patients, UC patients, and controls. 
Data represent mean values ± SEM. P < 0.0001 
by 1-way ANOVA.
Figure 4
Relative expression of proteasomal immunosubunits in Caco-2 cells. Differentiated Caco-2 cells were stimulated with LPS, TNF-α, and IFN-γ, 
and the expression of β1i (A), β2i (B), and β5i (C) was measured by real-time PCR. Data represent means ± SEM (n = 3).
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Proteasome inhibitor secreted by probiotic bacteria inhibits the chymotrypsin-like activity of 20S 
proteasomes isolated from CD patients and prevents nascent colitis in IL-10 KO mice. (A) The 
chymotrypsin-like activity of 20S proteasomes (2 μg) purified from CD patients (n = 6) was mea-
sured in the presence (50 μl) or absence of conditioned media from probiotic bacteria (VSL#3) 
and E. coli strain Nissle 1917. As control, the synthetic proteasome inhibitor MG132 was used 
at a concentration of 10 μM. (B) IL-10 KO mice were treated before the onset of colitis either 
with PBS- (control) or VSL#3-conditioned medium. Treatment started at the age of 10 weeks 
and was performed for 3 weeks by giving either 500 μl PBS or VSL#3 intragastrically every other 
day. Weight was monitored for both groups (n = 8).
Figure 6
Effect of immunoproteasomes on degradation of IκBα. (A) Kinet-
ics of IκBα degradation by 20S proteasomes purified from colonic 
mucosa of patients with IBD and controls (CD, n = 5; UC, n = 5; 
controls, n = 5). IκBα was in vitro translated in the presence of 
35S-methionine (Supplemental Figure 2) and incubated with iso-
lated 20S proteasomes for indicated times. C60 represents a 
control incubated for 60 minutes without 20S proteasomes with 
an equivalent amount of IκBα. (B) Quantitative evaluation of IκBα 
degradation by 20S proteasomes isolated from patients with IBD 
and controls in the absence of ATP. P < 0.0001 (by 1-way ANOVA); 
n = 5. (C) Analysis of degradation of in vitro–translated IκBα by 2 
different subsets of 20S proteasomes. Data from 1 representative 
experiment are shown for purified constitutive proteasomes (LCL 
721.174; n = 3) and immunoproteasomes (LCL 721; n = 3). Lack of 
β1i and β5i in LCL 721.174 excludes the incorporation of immuno-
subunits in 20S proteasomes. C90 represents a control line without 
20S proteasomes. (D) Quantification of IκBα degradation by 20S 
protesomes isolated from LCL 721 and LCL 721.174 cells (n = 3).
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Cytosolic and nuclear extracts obtained from colonic specimens analyzed 
by Western blot using antibodies directed against cytosolic p105 and p50 
as well as nuclear p65 and c-Rel proteins (CD, n = 9; UC, n = 9; controls, 
n = 10). HDAC2 was used as loading control for nuclear extracts.
Figure 9
Double immunofluorescence of proteasomal immunosub-
unit β2i and NF-κB subunit p65 in the terminal ileum and 
colon of IBD patients and controls. Magnification, ×1,000. 
Increased expression of NF-κB subunit p65 colocalizes 
with enhanced expression of the β2i subunit in intestinal 
epithelial cells and cells of the lamina propria (green fluo-
rescence, β2i; red fluorescence, p65). NF-κB was stained 
with a primary antibody that exclusively recognizes acti-
vated p65. Data represent 1 of 8–10 patients per group.
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Schematic overview of enhanced immu-
noproteasome-mediated NF-κB activa-
tion and consequent exacerbation of 
inflammation in CD patients. Unknown 
initial inflammatory events induce expres-
sion of c-Rel in the intestinal mucosa and 
a strong Th1 cell response via IL-12. 
High amounts of IFN-γ trigger generation 
of immunoproteasomes, which enhances 
NF-κB activation, thus perpetuating the 
inflammatory process.
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A  proteasome  inhibitor  prevents  activation  of 
NF-kappa B and stabilizes a newly phosphorylated 
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